Not checkedNot checked for notices yet.
Editorial: Immunological characteristics of malignant tumors of the hepatobiliary system and identification of immunotherapy targets
Qiyao Zhang, Qiyao Zhang, Qiyao Zhang and 9 more
Frontiers in Immunology · 2023
doi:10.3389/fimmu.2023.1142101 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Previous studies have demonstrated that large numbers of immune cells infiltrate the microenvironment of hepatobiliary malignant tumors. These immune cells play an important role in immune surveillance and immune clearance of tumors. However, hepatobiliary malignancies occur in the immune tolerance niche. The hepatobiliary system has various mechanisms to inhibit aberrant immune activation against antigens and bacteria transmitted through the portal vein system, including the upregulation of immune checkpoints (such as PDCD1) and the secretion of exosomes and cytokines (1). The efficacy of immune checkpoint inhibitors (ICIs) developed based on these known approaches has been verified in several cancers, including liver cancer and gall bladder cancer (GBC) (2). However, patients with hepatobiliary malignancies exhibit a low overall response rate (ORR) to the above treatments. The median overall survival time of patients with liver cancer and GBC is 16.4 and 13.9 months, respectively. ICIs exert an exact but limited therapeutic effect. Researchers have attempted to predict the sensitivity of treatment based on the expression of autoimmune checkpoint proteins, the secretion of target proteins via exosomes, and the degree of infiltration of T cells and macrophages in the tumor microenvironment (TME) (3). The combinations of two types of ICIs and ICIs and tyrosine kinase inhibitors or anti-VEGF antibodies can potentiate the effect of immunotherapy. However, the progress in the field of combinatorial therapy is not satisfactory. The mechanism underlying immune escape in the TME has not been completely elucidated. Future studies must evaluate the mechanisms involved in the selectivity of ICIs for hepatobiliary malignancies.Considering the importance of the treatment of malignant tumors of the hepatobiliary system, our research group aimed to elucidate the mechanisms involved in tumor cell- Although these six immune-related gene features are generated based on a small cohort, they exhibited good differentiation ability for patients with ICC receiving immunochemotherapy.Tumor mutational burden, neoantigen burden, and pre-infiltrating T cells are indicators of the benefit of immunosuppressive therapy at the checkpoint (6). Liu et al. studied the specific role of IMPDH1 in tumors. IMPDH1 can up-regulate the production of cytosine and promote the consumption of guanine, which is related to uncontrolled cell proliferation (7). The authors demonstrated that the expression of IMPDH1 was upregulated in various tumors and was associated with poor prognosis. IMPDH1 is not only a potential tumor prognostic marker and therapeutic target, but also plays an immunomodulatory role through CD8+T lymphocytes and mononuclear macrophages.Meanwhile, IMPDH1 is closely related to immune checkpoints and immune related genes and pathways in TME. The expression of IMPDH1 affects the efficacy and prognosis of ICI treatment in patients with cancer.Our research topic "Immunological Characteristics of Malignant Tumors of the Hepatobiliary System and Identification of Immunobiliary Targets" is the basis for this study on the mechanism of immune escape in the TME of hepatobiliary system malignancy and provided accurate evidence of the mechanism of highly selective ICIs in hepatobiliary malignancies. We believe that this research topic provides a high-level forum for further research on the immune mechanism and treatment of hepatobiliary malignancies.
Abstract licence: CC BY
References5
5 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.